SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We RADNOR, Pa.–(BUSINESS IV Ganaxolone in Pediatric Super-Refractory Status Epilepticus: Two Case Presentations.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

NewsMunchies

JULY 10, 2023

AI tools are gaining popularity in biomedical research because while it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, using AI could vastly accelerate the drug-development process. AI automation opens up the possibility of faster, cheaper pharmaceuticals.

Treatment 58

Treatment Research and Development Pharmaceutical Microdosing 58

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

United Patients Group

JANUARY 4, 2024

As we move forward into 2024 and beyond, the sector offers diverse paths beyond direct patient care. The growth stems from rising healthcare demand, facility expansion, and the imperative for efficient administration to maintain quality patient care. Adverse drug events (ADEs) affect approximately 7 per 100 hospitalized patients.

Research and Development 52

Research and Development Patients Data Policy 52

Cannabis Law Report

JUNE 7, 2021

The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. Securities and Exchange Commission (“SEC”) on July 13, 2020.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy.

Access 52

Access Patients Research and Development Treatment 52

SpeedWeed

MARCH 13, 2021

Almost 25% of patients with Parkinson’s disease reported that they had used cannabis in the prior six months in a survey from the Parkinson’s Foundation. Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. More Than 1,000 PD Patients Surveyed.

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our Work with U.S. Christy Curran.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. Data Bridge sees strong psychedelics growth.

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. billion, servicing nearly 340,000 active patients. In 2019, the island’s economy grew by 2.1% in real terms to £4.97 to reach 3.2

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JULY 7, 2021

The country, which Tilray said has an estimated medical marijuana demand of more than 100,000 patients, legalized the drug for medical use in 2017 but has since relied on importing it. What they’re asking is … for information,” she said, like how the products are used, how patients can be instructed, and what dosage is. “We

Clinical Trials 105

Clinical Trials Education Data Pharmaceutical 105

FloridaMarijuana.net

JUNE 27, 2018

The study’s data showed that “Cannabis significantly reduced ratings of depression, anxiety, and stress.” Participants in the study recorded their personal experience when using cannabis for their depression and other mental conditions such as anxiety and stress; scientists were able to use data collected from the app to analyze the results.

Treatment 100

Treatment Marijuana Conditions Data 100

Cannabis Law Report

APRIL 29, 2022

The product range is being manufactured to meet the growing demand for high quality medical cannabis products across Europe and builds on Curaleaf International being the first company to register a THC cannabis extract Active Pharmaceutical Ingredient (“API”) in Italy.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Patients 52

Cannabis Law Report

MARCH 22, 2020

A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza. World Health Organization (WHO).

THC 59

THC Clinical Trials Data Consumption 59

Veriheal

JANUARY 26, 2023

Most commonly, pharmaceutical medication is prescribed to regulate moods. However, pharmaceutical medications can have side effects, and they may take longer to work for many patients. Thus, this groundbreaking study laid the foundation for understanding how cannabinoids can support mental health.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

Veriheal

OCTOBER 3, 2022

With the growing acceptance and legalization of cannabis, the pharmaceutical industry is taking serious hits, according to a 2022 novel study into the impact of cannabis legalization on pharmaceutical firms. What Is the Pharmaceutical Industry? pharmaceuticals). Still, most pharmaceuticals are heavily processed.

Pharmaceutical 104

Pharmaceutical Patients Research and Development Legalization 104

Cannabis Law Report

JANUARY 28, 2022

By Maciej Konarowski, President of the Polish Medical Cannabis Patients Association and founder of the Can advocare law firm, and Conor O’Brien, Analyst at Prohibition Partners. Newly released data show that Poland is home to over 9,261 patients legally accessing medical cannabis, making it one of the largest such populations in Europe.

Legislation 52

Legislation Pharmaceutical Agriculture Cultivation 52

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

AUGUST 29, 2021

The export to Brazil also confirms the regulatory pathway and acts as a proof of concept in the largest market in South America where we aim to establish long-lasting supply relationships with our Brazilian pharmaceutical partners.”. 1 Source: Passport, Euromonitor International, Cannabis in Latin America, July 2021.

Extraction 98

Extraction Supply Chain Research and Development CBD 98

Veriheal

JUNE 19, 2023

The prominent players, as explained by the psychedelic market report, include Pfizer, Verrian, GlaxoSmithKline, COMPASS Pathways PLC, MindMed, Janssen Pharmaceuticals PLC, HAVN Life Sciences, Seelos Therapeutics, Field Trip Health, amongst others. Why Is the Psychedelics Market Growing? It was approved by the U.S.

Therapy 109

Therapy Treatment Patients Policy 109

United Patients Group

MAY 17, 2023

Recently, a pharmaceutical company has created a cannabis based isolate, meaning one cannabinoid, in this case CBD called Epidiolex which is available by prescription in all 50 states. Some ASD patients still feel that some THC is needed to truly experience the benefits of whole plant medicine in the treatment of ASD.

Sleep 78

Sleep Cannabinoids Patients CBD 78

CannaMD

NOVEMBER 22, 2020

Unfortunately, most traditional pharmaceutical options are distinctly lacking due to side effects, as well as a bit of trepidation (although Botox, one current treatment option for migraines, has gained popularity). Patients used the app, Strainprint, which allowed data to be archived and studied.

Marijuana 116

Marijuana Treatment Patients Cannabinoids 116

PrestoDoctor

SEPTEMBER 6, 2023

It has been a go-to option for healthcare professionals seeking to manage pain effectively for their patients. This has led many patients to explore cannabis as a potential substitute for prescription codeine. Additionally, common side effects such as drowsiness, constipation, and respiratory depression can be burdensome for patients.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105

Cannabis Law Report

JUNE 18, 2021

Minimum of 5 years of relevant industry experience in biotechnology or pharmaceutical companies demonstrating strong data mining and filtering skills. Global Data, PitchBook) to prepare competitive analysis assessments on new technologies. Adept at searching online databases (e.g.

Business 104

Business Research and Development Advocacy Data 104

Cannabis Law Report

AUGUST 18, 2022

Among the first in the nation, Phillips Lytle’s Psychedelics Practice Team combines expertise in pharmaceutical science, FDA regulations and risk management to serve the legal needs of emerging bio-tech sectors. “It also creates new opportunities for researchers, entrepreneurs, investors and pharmaceutical companies.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We So what will it mean that researchers may soon have dozens of producers and growers to choose from? “We

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133